Prostate specific antigen (PSA)-based screening

International Journal of Urology

Volumn 15, Issue 9, 2008, Pages 757-762

  Suzuki, Hiroyoshi ^b   Flanigan, Robert C ^a   Okuyama, Akihiko ^b  

^a American Urological Association   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER RISK; CANCER SCREENING; CLINICAL PRACTICE; EDITORIAL; HEALTH SURVEY; HUMAN; MEDICAL RESEARCH; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

HUMANS; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 51349160629     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2008.02122.x     Document Type: Editorial

References (28)

1. Matsubara A, Yasumoto H, Teishima J, Seki M, Mita K, Hasegawa Y, Yoshino T, Kato M, Usui T. Lower urinary tract symptoms and risk of prostate cancer in Japanese men. Int. J. Urol. 2006 13 : 1098 102.
2. Yasunaga H. Willingness to pay for mass screening for prostate cancer: a contingent valuation survey. Int. J. Urol. 2008 15 : 102 5.
3. Okihara K, Kitamura K, Okada K, Mikami K, Ukimura O, Miki T. Ten year trend in prostate cancer screening with high prostate-specific antigen exposure rate in Japan. Int. J. Urol. 2008 15 : 156 60.
4. Imamura T, Yasunaga H. Economic evaluation of prostate cancer screening with prostate-specific antigen. Int. J. Urol. 2008 15 : 285 8.
5. Kawamura K, Suzuki H, Kamiya N, Imamoto T, Yano M, Miura J, Shimbo M, Suzuki N, Nakatsu H, Ichikawa T. Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL. Int. J. Urol. 2008 15 : 598 62.
6. Cancer Stat Fact Sheets - Cancer of the Prostate 2006 Cited 21 Mar 2007.] Available from URL: http://seer.cancer.gov/statfacts/html/prost.html
7. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J. Clin. 2007 57 : 43 66.
8. Ilic D, O'Connor D, Green S, Wilt T. Screening for prostate cancer. Cochrane Database Syst. Rev. 2006 3 : CD R, Lohr KN. Screening for prostate cancer: An update of the evidence for the US Preventive Services Task Force. Ann. Intern. Med. 2002 137 : 917 29.
9. Fowler FJ Jr., Walker-Corkery MJ, Barry B et al. The impact of a suspicious prostate biopsy on patients' psychological, socio- behavioral, and medical care outcomes. J. Gen. Intern. Med. 2006 21 : 715 21.
10. Katz DA, Jarrard DF, McHorney CA, Hillis SL, Wiebe DA, Fryback DG. Health perceptions in patients who undergo screening and workup for prostate cancer. Urology 2007 69 : 215 20.
11. Ransohoff DF, McNaughton Collins M, Fowler FJ. Why is prostate cancer screening so common when the evidence is so uncertain? A system without negative feedback. Am. J. Med. 2002 113 : 663 7.
12. Kaufman DS, McDougal WS, Zietman AL, Young RH. Case 18-2007: A 54-year-old man with early-stage prostate cancer. N. Engl. J. Med. 2007 356 : 2515 19.
13. Agency for Healthcare Research and Quality. Screening for Prostate Cancer: Recommendations and Rationale. 2002 Cited 20 May 2007.] Available from URL: http://www.ahrq.gov/clinic/3rduspstf/prostatescr/prostaterr.htm
14. Volk RJ, Hawley ST, Kneuper S et al. Trials of decision AIDS for prostate cancer screening a systematic review. Am. J. Prev. Med. 2007 33 : 428 34.
15. Guerra CE, Jacobs SE, Holmes JH, Shea JA. Are physicians discussing prostate cancer screening with their patients and why or why not? A pilot study. J. Gen. Intern. Med. 2007 22 : 901 7.
16. Gohagan JK, Prorok PC, Hayes RB, Kramer BS. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: History, organization, and status. Control. Clin. Trials. 2000 6 (21 Suppl 251S 272S.
17. Schroder FH, Kranse R, Rietbergen J, Hoedemaeke R, Kirkels W. The European Randomized Study of Screening for Prostate Cancer (ERSPC): An update. Members of the ERSPC, Section Rotterdam. Eur. Urol. 1999 35 : 539 43.
18. Etzioni R, Penson DF, Legler JM et al. Overdiagnosis due to prostate-specific antigen screening: Lessons from US Prostate cancer incidence trends. J. Natl. Cancer Inst. 2002 94 : 981 90.
19. Draisma G, Boer R, Otto SJ et al. Lead times and overdetection due to prostate specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J. Natl. Cancer Inst. 2003 95 : 868 78.
20. Wang Yu-N, Mitra N, Hudes M et al. Survival associated with vs. observation localized prostate cancer in elderly men. JAMA 2006 296 : 2683 93.
21. Epstein JI, Chan DW, Sokoll LJ et al. Nonpalpable stage T1c prostate cancer: Prediction of insignificant disease using free/Total prostate specific antigen levels and needle biopsy findings. J. Urol. 1998 160 : 2407 11.
22. Bartsch G, Horninger W, Oberaigner W et al. Tyrolean screening study: Update 2005 - Stage migration and decrease of mortality. J. Urol. 2006 175 (Suppl).
23. Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J. Urol. 1994 152 : 1714 20.
24. Graif T, Yu X, Loeb St et al. Underdiagnosis and overdiagnosis of prostate cancer. J. Urol. 2006 175 (4 Suppl).
25. Boyle P. Screening for prostate cancer: Have you had your cholesterol measured? BJU Int. 2003 92 : 191 9.
26. Jemal A, Ward E, Wu Y, Martin HJ, McLaughlin CC, Thun MJ. Geographic patterns of proste cancer mortality and variations in access to medical care in the United States. Cancer Epidemiol. Biomarkers Prev. 2005 14 : 590 5.
27. Jemal A, Murrey T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics. CA Cancer J. Clin. 2003 53 : 5 26.
28. Bartsch G, Horninger W, Klocker H et al. Prostate cancer mortality after introduction of prostate specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001 58 : 417 27.